We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BVXP Bioventix Plc

0.00 (0.00%)
Last Updated: 08:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Bioventix Plc BVXP London Ordinary Share
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 4,600.00 08:00:00
Open Price Low Price High Price Close Price Previous Close
4,600.00 4,600.00 4,600.00 4,600.00
more quote information »
Industry Sector

Bioventix BVXP Dividends History

Announcement Date Type Currency Dividend Amount Ex Date Record Date Payment Date

Top Dividend Posts

Top Posts
Posted at 25/3/2024 10:39 by melody9999
I see Cavendish have raised their price target to 5900p from 4400p in Oct 23. Will be happy to see the BVXP once again climb above the Cavendish target price!
Posted at 12/2/2024 12:37 by maddox
BVXP are in the running to develop what has been described as the 'Holy Grail' of diagnostic testing - an early stage Alzheimer's test.

BBC Radio 4 Today report on new Alzheimer's treatments. Mentions that there are about 28 dementia drugs in late stage development. Whilst the current two leading drugs show efficacy the promise is of better drugs being developed.

The need for an early stage diagnostic test is clear in this report. Arguably, it's equally as important to have a simple early stage test as the drugs.
Posted at 24/1/2024 09:15 by alter ego
well researched 1c3479z. You're correct. I had conformation from Peter Harrison this morning. It does however, show the potential of the work being done by BVXP in this field.
Posted at 23/1/2024 16:42 by 1c3479z
not convinced- the journal article refers to an ALZpath validated immunoassay, did ALZpath also provide the antibody?
in any case, should this be validated, one expects the BVXP pTau 217 might have advantages over mouse monoclonals and be commercially in high demand from various diagnostics companies eg Roche etc with a long life cycle.
Posted at 23/1/2024 10:08 by alter ego
Can't be certain but it sounds like a BVXP SMA.

Sky news report today mentions " Measuring levels of a protein called p-tau217 in the blood...." "The study from Dr Nicholas Ashton at the University of Gothenburg, and colleagues, is published in the Jama Neurology journal."

From BVXP Annual Report for year ended 30/6/23

"A leading blood biomarker for “A” is a phosphorylated form of tau called pTau217. A prototype assay from Gothenburg using an SMA has now been established which has performed well with frozen patient samples from a number of different cohorts." and
"A novel blood-based prototype assay for neurodegeneration (N) using another Tau SMA has also been developed in Gothenburg. This work clearly supports the potential utility of this blood test and further work is ongoing in Gothenburg with further publications planned."
Posted at 12/12/2023 08:29 by strollingmolby
I missed this at the time, and can't see it was posted previously - BVXP was featured in the IC the day after the results, noting it as a buy at £34:
Posted at 08/12/2023 18:05 by strollingmolby
There is a brief mention of BVXP in The Motley Fool today - may have created some buying volume.
Posted at 02/11/2023 08:05 by melody9999
forced redemption reflection on BVXP
Posted at 31/10/2023 09:48 by maddox
If you top-up now at our shorted depressed price you'll be locking in a nice yield of c.4%.

One further point the 2023 dividends of 152p looks to be no change on 2022. However, the 152p paid in 2022 included one of BVXP's regular special dividends of 26p. So, excluding this the dividends increased a very healthy 20.6%!

In the last five years BVXP has paid three Special Dividends - so that 4% is probably understated albeit the corp tax increase will slow cash accumulation.
Posted at 30/10/2023 10:28 by 74tom
@Big7time, 2017 earnings were 96p, so earnings grow has been nowhere near 3x in that time period. At the start of 2017 it was trading at £13.50 so a 1 year forward P/E of around 14x, by the end of 2017 shares had jumped to £25 as the P/E multiple exploded, this was justified as the EPS growth was significant (43% from 2016-2017).

Where is the evidence of that EPS growth right now?

At 14x it would be valued at £22.40 with a dividend yield of 6.7%, in the current interest rate environment that would make sense & be a more attractive level to invest.

I suspect shares derate to somewhere between there and present levels - let's see.

Your Recent History

Delayed Upgrade Clock